Platelet Aggregation Inhibitors

• 

  Subject Areas on Research

  • "Blueprinting" thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. 
  • "Rescue" platelet GP IIb/IIIa inhibitor therapy in percutaneous coronary intervention: bailing out of a sunken ship. 
  • 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. 
  • 2002 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: implications for emergency department practice. 
  • 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. 
  • 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. 
  • 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 
  • 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. 
  • 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. 
  • 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. 
  • 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial. 
  • A Bigger Look Into the "Therapeutic Window" of Platelet Reactivity to Adenosine Diphosphate. 
  • A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. 
  • A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. 
  • A New Protocol for Anticoagulation With Tirofiban During Flow Diversion. 
  • A Systematic Review of Clopidogrel Resistance in Vascular Surgery: Current Perspectives and Future Directions. 
  • A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. 
  • A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. 
  • A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. 
  • A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. 
  • A freeze on tailored antiplatelet therapy? 
  • A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. 
  • A marriage of enhancement: fibrinolysis and conjunctive therapy. 
  • A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). 
  • A new method of representing drug-induced platelet inhibition: better description of time course, response variability, non-response, and heightened activity. 
  • A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. 
  • A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study. 
  • A novel method to assess platelet inhibition by eptifibatide with thrombelastograph. 
  • A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators. 
  • A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. 
  • A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. 
  • A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes. 
  • A risk score to predict bleeding in patients with acute coronary syndromes. 
  • A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes. 
  • A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. 
  • A thought experiment in contemporary drug development: informed bench-to-bedside strategies. 
  • ACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement. 
  • ACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement. 
  • ACP Journal Club. Review: In patients having PCI, high-dose clopidogrel reduces major cardiac events vs standard-dose clopidogrel. 
  • ANTARCTIC: platelet function testing to adjust therapy. 
  • ARC-HBR criteria and TAVR: not all high bleeding risk patients look alike. 
  • AZD6140. 
  • Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. 
  • Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. 
  • Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study. 
  • Abciximab readministration: results of the ReoPro Readministration Registry. 
  • Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. 
  • Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. 
  • Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. 
  • Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. 
  • Acceptance of high platelet reactivity as a risk factor: now, what do we do about it? 
  • Acetylsalicylic acid and clopidogrel hyporesponsiveness following acute coronary syndromes. 
  • Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin. 
  • Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. 
  • Acute Limb Ischemia in Peripheral Artery Disease. 
  • Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. 
  • Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. 
  • Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 
  • Acute coronary syndromes and diabetes mellitus. 
  • Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. 
  • Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. 
  • Acute profound thrombocytopenia after c7E3 Fab therapy. 
  • Adding ezetimibe to simvastatin improved cardiovascular outcomes in stable acute coronary syndrome. 
  • Additional Factors in Considering Patent Foramen Ovale Closure to Prevent Recurrent Ischemic Stroke. 
  • Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. 
  • Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. 
  • Adjuvant therapy for intracoronary stents. Investigations in atherosclerotic swine. 
  • Advances in antiplatelet therapy: agents in clinical development. 
  • Advances in prevention and health services delivery 2009. 
  • Advances in prevention and health services delivery 2010-2011. 
  • Advances in stroke: Prevention and health services delivery 2012-2013. 
  • Advances in the approach to acute coronary syndromes. 
  • Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. 
  • Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. 
  • Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial. 
  • An analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association non-ST-segment elevation myocardial infarction guideline adherence. 
  • An antiplatelet response gene expression signature is associated with bleeding. 
  • An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. 
  • An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. 
  • Anabolic steroids, acute myocardial infarction and polycythemia: a case report and review of the literature. 
  • Analysis of Prescriptions for Dual Antiplatelet Therapy After Acute Ischemic Stroke. 
  • Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention. 
  • Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). 
  • Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. 
  • Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy. 
  • Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). 
  • Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). 
  • Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement. 
  • Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT. 
  • Anticoagulation and antiplatelet therapy in stable coronary artery disease: A multicenter survey. 
  • Antidote control of aptamer therapeutics: the road to a safer class of drug agents. 
  • Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. 
  • Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. 
  • Antiplatelet Medications Are Associated With Bleeding and Decompensation Events Among Patients With Cirrhosis. 
  • Antiplatelet Therapy in Staphylococcus aureus Bacteremia: No Time Like the Past? 
  • Antiplatelet Use and Ischemic Stroke Risk in Minor Stroke or Transient Ischemic Attack: A Post Hoc Analysis of the POINT Trial. 
  • Antiplatelet agents and bleeding after cardiac surgery. 
  • Antiplatelet agents in cardiovascular disease. 
  • Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. 
  • Antiplatelet and anticoagulant prophylaxis and postoperative blood loss in cardiac surgery. 
  • Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? 
  • Antiplatelet and antithrombin therapies in the acute coronary syndromes. 
  • Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4. 
  • Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. 
  • Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. 
  • Antiplatelet patterns and outcomes in patients with atrial fibrillation not prescribed an anticoagulant after stroke. 
  • Antiplatelet resistance--fact or myth? 
  • Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. 
  • Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. 
  • Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients. 
  • Antiplatelet therapy and platelet function testing. Introduction. 
  • Antiplatelet therapy beyond 2012: role of personalized medicine. 
  • Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions. 
  • Antiplatelet therapy in older adults with non-ST-segment elevation acute coronary syndrome: considering risks and benefits. 
  • Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. 
  • Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. 
  • Antiplatelet therapy in pediatric cardiovascular patients. 
  • Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. 
  • Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. 
  • Antiplatelet therapy: Clopidogrel-PPI interaction, an ongoing controversy. 
  • Antiplatelet therapy: What have we learned from the ANTARCTIC trial? 
  • Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. 
  • Antiplatelet treatment of cardiovascular disease: a translational research perspective. 
  • Antithrombotic Therapy After Peripheral Vascular Intervention. 
  • Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. 
  • Antithrombotic Therapy and Cardiovascular Outcomes After Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation. 
  • Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. 
  • Antithrombotic effect of ticlopidine in an experimental model of retinal vein occlusion. 
  • Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. 
  • Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician. 
  • Antithrombotic therapy in atrial fibrillation. 
  • Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes. 
  • Antithrombotic therapy in patients undergoing coronary angioplasty. 
  • Antithrombotic therapy in patients undergoing percutaneous coronary intervention. 
  • Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. 
  • Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5). 
  • Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial. 
  • Apixaban after acute coronary syndrome. 
  • Apixaban with antiplatelet therapy after acute coronary syndrome. 
  • Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. 
  • Applying antithrombotic therapies to improve outcomes in patients with atrial fibrillation. 
  • Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. 
  • Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. 
  • Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. 
  • Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). 
  • Aspirin and clopidogrel resistance: consideration and management. 
  • Aspirin and the prevention of venous thromboembolism. 
  • Aspirin effects on platelet gene expression are associated with a paradoxical, increase in platelet function. 
  • Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. 
  • Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis. 
  • Aspirin in cardiovascular disorders. What is the optimum dose? 
  • Aspirin resistance and a single gene. 
  • Aspirin resistance. 
  • Aspirin treatment after myocardial infarction: are health maintenance organization members, women, and the elderly undertreated? 
  • Aspirin use during pregnancy and hypoxia-related placental pathology. 
  • Aspirin: it's hard to beat. 
  • Assessing the current role of platelet function testing. 
  • Assessing the value of newer pharmacologic agents in non-ST elevation patients: a decision support system application. 
  • Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. 
  • Assessment of oral antithrombotic therapy by platelet function testing. 
  • Association Between Previous Use of Antiplatelet Therapy and Intracerebral Hemorrhage Outcomes. 
  • Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial. 
  • Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. 
  • Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. 
  • Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. 
  • Association between patient beliefs and medication adherence following hospitalization for acute coronary syndrome. 
  • Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. 
  • Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. 
  • Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial. 
  • Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. 
  • Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID Trial. 
  • Association of Intracerebral Hemorrhage Among Patients Taking Non-Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. 
  • Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. 
  • Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. 
  • Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines. 
  • Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. 
  • Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). 
  • Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. 
  • Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry. 
  • Association of race with complications and prognosis following acute coronary syndromes. 
  • Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. 
  • Atrial Fibrillation and Coronary Artery Disease: A Long-Term Perspective on the Need for Combined Antithrombotic Therapy. 
  • Atrial Fibrillation and Percutaneous Coronary Intervention. 
  • Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. 
  • Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. 
  • Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. 
  • Balancing the Risks and Benefits of Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery. 
  • Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients - a report from the National Cardiovascular Data Registry. 
  • Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. 
  • Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. 
  • Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction. 
  • Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population. 
  • Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. 
  • Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. 
  • Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. 
  • Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Beta-blocker therapy in advanced heart failure: clinical characteristics and long-term outcomes. 
  • Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. Focus on isolated coronary artery bypass grafting and oral irreversible P2Y(12) receptor antagonists. 
  • Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes. 
  • Biosignatures in thrombotic disorders. 
  • Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. 
  • Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. 
  • Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. 
  • Bleeding after antithrombotic therapy in patients with acute ischemic heart disease: is it the drugs or how we use them? 
  • Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. 
  • Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. 
  • Bleeding avoidance strategies in percutaneous coronary intervention. 
  • Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. 
  • Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS. 
  • Bleeding in acute coronary syndromes. 
  • Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. 
  • Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass. 
  • Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week. 
  • Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. 
  • Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. 
  • Building evidence for early initiation of clopidogrel loading in non-ST-segment elevation acute coronary syndromes: going past the American College of Cardiology/American Heart Association guidelines. 
  • COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial. 
  • CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. 
  • CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials. 
  • CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. 
  • Canadian stroke best practice consensus statement: Secondary stroke prevention during pregnancy. 
  • Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry. 
  • Cangrelor and Heparin for Pulmonary Thromboendarterectomy in Heparin-Induced Thrombocytopenia. 
  • Cangrelor for the treatment of patients with Arterial Thrombosis. 
  • Cangrelor use prior to left ventricular assist device surgery: a case series. 
  • Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds. 
  • Cardiac allograft vasculopathy after heart transplantation: current prevention and treatment strategies. 
  • CardioPulse: Platelet inhibitors and their differences. 
  • Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial. 
  • Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. 
  • Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial. 
  • Carotid web: an occult mechanism of embolic stroke. 
  • Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. 
  • Cause of Death Among Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. 
  • Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. 
  • Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. 
  • Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. 
  • Changes in Medical Management after Coronary CT Angiography. 
  • Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease. 
  • Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. 
  • Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. 
  • Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial. 
  • Chronic kidney disease and stroke. 
  • Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients. 
  • Cigarette Smoking, Clopidogrel Responsiveness, and Hemoglobin Level. 
  • Cigarette smoking and clopidogrel interaction. 
  • Cilostazol to overcome high on-treatment platelet reactivity in korean patients treated with clopidogrel and calcium-channel blocker. 
  • Classification and treatment of endothermal heat-induced thrombosis: Recommendations from the American Venous Forum and the Society for Vascular Surgery. 
  • Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage. 
  • Clinical Characteristics, Procedural Factors, and Outcomes of Percutaneous Coronary Intervention in Patients With Mechanical and Bioprosthetic Heart Valves. 
  • Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues. 
  • Clinical and research issues regarding chronic advanced coronary artery disease: part I: Contemporary and emerging therapies. 
  • Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. 
  • Clinical application of cardiovascular pharmacogenetics. 
  • Clinical application of pharmacogenetics: focusing on practical issues. 
  • Clinical applications of antiplatelet therapy. 
  • Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. 
  • Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. 
  • Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial. 
  • Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. 
  • Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. 
  • Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. 
  • Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials. 
  • Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. 
  • Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators. 
  • Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. 
  • Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). 
  • Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. 
  • Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. 
  • Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists. 
  • Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. 
  • Clopidogrel and PPI interaction: clinically relevant or not? 
  • Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. 
  • Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. 
  • Clopidogrel does not induce fibrinolysis in healthy subjects. 
  • Clopidogrel dosing in overweight patients: does one size fit all? 
  • Clopidogrel efficacy and cigarette smoking status. 
  • Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. 
  • Clopidogrel in infants with systemic-to-pulmonary-artery shunts. 
  • Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. 
  • Clopidogrel plus aspirin in atrial fibrillation. 
  • Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy. 
  • Clopidogrel resistance: implications for coronary stenting. 
  • Clopidogrel resistance? 
  • Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey. 
  • Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. 
  • Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. 
  • Clopidogrel use and bleeding after coronary artery bypass graft surgery. 
  • Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database. 
  • Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. 
  • Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. 
  • Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting. 
  • Clopidogrel: the future choice for preventing platelet activation during coronary stenting? 
  • Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. 
  • Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications. 
  • Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. 
  • Coagulopathy of Coronavirus Disease 2019. 
  • Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. 
  • Combination fibrinolytic therapy and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction: an emerging solution for reperfusion. 
  • Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. 
  • Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. 
  • Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. 
  • Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. 
  • Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use. 
  • Community pharmacists' experience with pharmacogenetic testing. 
  • Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. 
  • Comparative Effectiveness of Medical Therapy, Supervised Exercise, and Revascularization for Patients With Intermittent Claudication: A Network Meta-analysis. 
  • Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials. 
  • Comparative effectiveness review of antiplatelet agents in peripheral artery disease. 
  • Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents. 
  • Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention. 
  • Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. 
  • Comparison of Outcomes and Costs Associated With Aspirin ± Clopidogrel After Coronary Artery Bypass Grafting. 
  • Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). 
  • Comparison of angioplasty with stenting in acute myocardial infarction. 
  • Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. 
  • Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy). 
  • Comparison of clinical characteristics, treatments and outcomes of patients with ST-elevation acute myocardial infarction with versus without new or presumed new left bundle branch block (from NCDR®). 
  • Comparison of long-term outcomes between older Asian and white patients with non-ST-segment elevation myocardial infarction: findings from CRUSADE-CMS database. 
  • Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial). 
  • Comparison of one-year outcomes...ESPRIT. Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy. 
  • Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. 
  • Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. 
  • Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. 
  • Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. 
  • Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial: Lessons Learned From ADAPTABLE. 
  • Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. 
  • Concomitant use of proton pump inhibitors and dual antiplatelet therapy for cardiovascular outcomes. 
  • Conditions influencing the interaction of asialo von Willebrand factor with human platelets--the effects of external ionized calcium concentration and the role of arachidonate pathway. 
  • Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review. 
  • Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine. 
  • Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. 
  • Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. 
  • Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. 
  • Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. 
  • Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. 
  • Contemporary pharmacological reperfusion in ST elevation myocardial infarction. 
  • Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. 
  • Continuum of care in the treatment of ST-segment elevation myocardial infarction (STEMI): importance of platelet and coagulation inhibition. 
  • Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. 
  • Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery. 
  • Conversations in cardiology: bridging antiplatelet therapy before surgery. 
  • Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes: Findings From the ARTEMIS Trial. 
  • Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. 
  • Coronary intervention and glycoprotein IIb/IIIa integrin blockade. 
  • Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. 
  • Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis. 
  • Cost effectiveness of abciximab during routine medical practice. 
  • Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. 
  • Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes. 
  • Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty. 
  • Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. 
  • Could coenzyme Q10 affect hemostasis by inhibiting platelet vitronectin (CD51/CD61) receptor? 
  • Covalent immobilization of RGDS on hydrogel surfaces to direct cell alignment and migration. 
  • Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. 
  • Current evidence and clinical implications of aspirin resistance. 
  • Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. 
  • Current options in oral antiplatelet strategies during percutaneous coronary interventions. 
  • Current status of cardiac surgery in the abciximab-treated patient. 
  • Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). 
  • Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. 
  • Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. 
  • Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS. 
  • Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. 
  • Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. 
  • Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes. 
  • Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough. 
  • Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma. 
  • Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. 
  • Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. 
  • Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B2 and agonist-induced platelet aggregation. 
  • Delivery of glycoprotein IIb/IIIa inhibitor therapy for percutaneous coronary intervention: why not take the intracoronary highway? 
  • Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators. 
  • Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention. 
  • Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. 
  • Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. 
  • Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial. 
  • Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial. 
  • Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. 
  • Design, progress and challenges of a double-blind trial of warfarin versus aspirin for symptomatic intracranial arterial stenosis. 
  • Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. 
  • Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. 
  • Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. 
  • Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. 
  • Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. 
  • Diagnosis and treatment of acute coronary ischemic syndromes: a update for 1995. 
  • Diagnostic and Therapeutic Yield of Endoscopy in Patients with Elevated INR and Gastrointestinal Bleeding. 
  • Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment. 
  • Differences in short-term versus long-term outcomes of older black versus white patients with myocardial infarction: findings from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of American College of Cardiology/American Heart Association Guidelines (CRUSADE). 
  • Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel. 
  • Difficulties in applying clinical trial information to the practice setting: case of a high-cost drug. 
  • Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes: A Systematic Review and Meta-analysis. 
  • Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. 
  • Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. 
  • Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy? 
  • Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial. 
  • Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity? 
  • Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission? 
  • Doing the right things and doing them the right way: association between hospital guideline adherence, dosing safety, and outcomes among patients with acute coronary syndrome. 
  • Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. 
  • Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. 
  • Dosing and administration of ReoPro (c7E3 Fab). 
  • Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. 
  • Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. 
  • Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. 
  • Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. 
  • Dropping P2Y12 inhibitors in patients with AF undergoing PCI? Not yet a SAFE bet. 
  • Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. 
  • Drug insight: Clopidogrel nonresponsiveness. 
  • Drug-Eluting Versus Bare-Metal Stents in Older Patients: A Meta-Analysis of Randomized Controlled Trials. 
  • Drug-company sponsorship and the Declaration of Helsinki. 
  • Drugs for percutaneous coronary interventions. 
  • Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). 
  • Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. 
  • Dual antiplatelet therapy after stent implantation. 
  • Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials. 
  • Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery. 
  • Dual antiplatelet therapy in aneurysmal subarachnoid hemorrhage: association with reduced risk of clinical vasospasm and delayed cerebral ischemia. 
  • Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization. 
  • Dual antiplatelet therapy with or without oral anticoagulation in the postdischarge management of acute coronary syndrome patients with an indication for long term anticoagulation: a systematic review. 
  • Dual antiplatelet therapy. 
  • Dual versus triple antithrombotic therapy after percutaneous coronary intervention or acute coronary syndrome in patients with indication for anticoagulation: an updated meta-analysis. 
  • Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis. 
  • Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. 
  • Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. 
  • Durability of platelet inhibition by clopidogrel. 
  • Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. 
  • Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. 
  • ED disposition of the Glasgow Coma Scale 13 to 15 traumatic brain injury patient: analysis of the Transforming Research and Clinical Knowledge in TBI study. 
  • ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). 
  • ESPRIT in context: pharmacology matters! 
  • Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. 
  • Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome). 
  • Early Medication Nonadherence After Acute Myocardial Infarction: Insights into Actionable Opportunities From the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. 
  • Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor. 
  • Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. 
  • Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial. 
  • Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. 
  • Early intervention: which patients and how early? 
  • Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention. 
  • Early statin initiation and outcomes in patients with acute coronary syndromes. 
  • Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. 
  • Early treatment for non-ST-segment elevation acute coronary syndrome is associated with appropriate discharge care. 
  • Early versus delayed, provisional eptifibatide in acute coronary syndromes. 
  • Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. 
  • Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. 
  • Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. 
  • Economic effects of extended clopidogrel therapy--a word of caution. 
  • Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. 
  • Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. 
  • Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users. 
  • Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data. 
  • Editorial commentary: MicroRNAs as effectors and indicators of aspirin therapeutic potential. 
  • Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. 
  • Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. 
  • Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl). 
  • Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial. 
  • Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial. 
  • Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. 
  • Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial. 
  • Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study. 
  • Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial. 
  • Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). 
  • Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study. 
  • Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. 
  • Effect of aspirin response signature gene expression on preterm birth and preeclampsia among women with lupus: a pilot study. 
  • Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. 
  • Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). 
  • Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy. 
  • Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. 
  • Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy. 
  • Effect of dipyridamole plus aspirin on hemodialysis graft patency. 
  • Effect of dual versus mono antiplatelet therapy on recurrent stroke modulated by activated partial thromboplastin time. 
  • Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. 
  • Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience. 
  • Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). 
  • Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. 
  • Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. 
  • Effect of low frequency ultrasound on combined rt-PA and eptifibatide thrombolysis in human clots. 
  • Effect of magnesium sulphate infusion on ex vivo platelet aggregation in swine. 
  • Effect of operator and institutional volume on clinical outcomes after percutaneous coronary interventions performed in Canada and the United States: a brief report from the Enhanced Suppression of the Platelet glycoprotein IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) study. 
  • Effect of oral pentoxifylline on cystoid macular edema associated with central retinal vein occlusion. 
  • Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. 
  • Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. 
  • Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. 
  • Effectiveness and safety of abciximab after failed thrombolytic therapy. 
  • Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention. 
  • Effects of 9, 12, 15-octadecatrien-6-ynoic acid on the metabolism of arachidonic acid in platelets and on platelet aggregation. 
  • Effects of 9,12,15-octadecatrien-6-ynoic acid on the metabolism of arachidonic acid in platelets and on the platelet aggregation. 
  • Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. 
  • Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. 
  • Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits. 
  • Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy. 
  • Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. 
  • Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. 
  • Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD. 
  • Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. 
  • Efficacy of abciximab readministration in coronary intervention. 
  • Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. 
  • Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study. 
  • Efficacy of clopidogrel for stroke depends on CYP2C19 genotype and risk profile. 
  • Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. 
  • Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. 
  • Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study. 
  • Embolic protection and platelet inhibition during renal artery stenting. 
  • Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors. 
  • Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators. 
  • Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. 
  • Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. 
  • Eptifibatide in coronary intervention: past time for the next chapter. 
  • Eptifibatide in percutaneous coronary intervention. A review. 
  • Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. 
  • Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention. 
  • Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures. 
  • Evaluating the generalizability of a large streamlined cardiovascular trial: comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data Registry. 
  • Evaluating the impact of public health notification: Duke clopidogrel experience. 
  • Evaluation of CRUSADE and ACUITY-HORIZONS Scores for Predicting Long-term Out-of-Hospital Bleeding after Percutaneous Coronary Interventions. 
  • Evaluation of Evidence-Based Dual Antiplatelet Therapy for Secondary Prevention in US Patients With Acute Ischemic Stroke. 
  • Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. 
  • Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. 
  • Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. 
  • Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance': a rebuttal. 
  • Evidence-based therapies and mortality in patients hospitalized in December with acute myocardial infarction. 
  • Examining biology and pharmacology-based hypotheses in the PLATO trial. 
  • Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. 
  • Excess of Solid Cancers After Prasugrel: The Food and Drug Administration Outlook. 
  • Executive Summary: Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. 
  • Exploring Meaningful Patient Engagement in ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness). 
  • Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysis. 
  • Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. 
  • Extending the Product Label for Ticagrelor: Looking Under the FDA Hood. 
  • Extending the indications of flow diversion to small, unruptured, saccular aneurysms of the anterior circulation. 
  • Extensive thrombus prior to elective percutaneous coronary intervention. 
  • External Ventricular Drain and Hemorrhage in Aneurysmal Subarachnoid Hemorrhage Patients on Dual Antiplatelet Therapy: A Retrospective Cohort Study. 
  • External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry. 
  • Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. 
  • Facilitated percutaneous coronary intervention in acute myocardial infarction: attractive concept but difficult to prove! 
  • Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. 
  • Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. 
  • Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2. 
  • Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. 
  • Fibrinolysis or primary PCI in myocardial infarction. 
  • Final results of the ReoPro readministration registry. 
  • First In-Human Experience With Inhaled Acetylsalicylic Acid for Immediate Platelet Inhibition: Comparison With Chewed and Swallowed Acetylsalicylic Acid. 
  • First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. 
  • First report of the point-of-care TEG: A technical validation study of the TEG-6S system. 
  • Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. 
  • Fondaparinux therapy in a hemodialysis patient with heparin-induced thrombocytopenia type II. 
  • For how long should treatment with clopidogrel be continued after coronary stent implantation? 
  • Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. 
  • Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). 
  • Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. 
  • From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). 
  • Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes. 
  • Future alternatives to heparin: low-molecular-weight heparin and hirudin. 
  • G-protein-coupled receptors as signaling targets for antiplatelet therapy. 
  • G-protein-coupled receptors signaling pathways in new antiplatelet drug development. 
  • GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. 
  • GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents? 
  • GP IIb/IIIa blockade in elective percutaneous coronary intervention. 
  • Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. 
  • Generic clopidogrel: time to substitute? 
  • Genetic influences on aspirin response in patients undergoing percutaneous coronary intervention. 
  • Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development. 
  • Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. 
  • Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. 
  • Genotyping: one piece of the puzzle to personalize antiplatelet therapy. 
  • Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. 
  • Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study. 
  • Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). 
  • Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. 
  • Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. 
  • Glycoprotein IIb/IIIa inhibitors: therapeutic applications in acute ST-segment elevation myocardial infarction. 
  • Glycoprotein IIb/IIIa integrin blockade. 
  • Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: a review of trial reports. 
  • Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. 
  • Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. 
  • Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. 
  • Guidelines for carotid endarterectomy: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. 
  • Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. 
  • Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. 
  • Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. 
  • HIV infection, ACS, PCI and high platelet reactivity: ingredients for a perfect thrombotic storm. 
  • HVAD: The ENDURANCE Supplemental Trial. 
  • Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. 
  • Hemorrhage associated with ventriculoperitoneal shunt placement in aneurysmal subarachnoid hemorrhage patients on a regimen of dual antiplatelet therapy: a retrospective analysis. 
  • Hemorrhagic complications of thoracentesis and small-bore chest tube placement in patients taking clopidogrel. 
  • Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. 
  • High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases. 
  • High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low? 
  • High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype. 
  • Highlights from the American Heart Association annual scientific sessions 2001: November 11 to 14, 2001. 
  • Hospital variability in the rate of finding obstructive coronary artery disease at elective, diagnostic coronary angiography. 
  • Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. 
  • How can modeling best contribute to the assessment of secondary stroke prevention strategies? 
  • How can we optimize the processes of care for acute coronary syndromes to improve outcomes? 
  • How country-specific should a country-specific cost-effectiveness analysis be? 
  • Hyperglycemia, Risk of Subsequent Stroke, and Efficacy of Dual Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial. 
  • Hypothesis: Presymptomatic treatment of Sturge-Weber Syndrome With Aspirin and Antiepileptic Drugs May Delay Seizure Onset. 
  • Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding. 
  • ISTH guidelines for antithrombotic treatment in COVID-19. 
  • Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAM8. 
  • Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee. 
  • Identifying Sex Dimorphism in Peripheral Artery Disease with Platelet Mapping. 
  • Iloprost in alginate decreases the thrombogenicity of expanded polytetrafluoroethylene. 
  • Image-Guided Percutaneous Gastrostomy Tube Placement is Safe in Patients Requiring Aspirin 325 mg. 
  • Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. 
  • Immunity to thrombotic events is achievable if we stop the guessing game: is this the major hidden message from GRAVITAS? 
  • Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. 
  • Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. 
  • Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. 
  • Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. 
  • Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome. 
  • Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy. 
  • Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial. 
  • Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. 
  • Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial. 
  • Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance Programs. 
  • Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. 
  • Impact of anticoagulation/antiplatelet therapy on femoropopliteal bypass graft outcomes. 
  • Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). 
  • Impact of carotid endarterectomy on medical secondary prevention after a stroke or a transient ischemic attack: results from the Reduction of Atherothrombosis for Continued Health (REACH) registry. 
  • Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. 
  • Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. 
  • Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. 
  • Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. 
  • Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. 
  • Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes. 
  • Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. 
  • Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. 
  • Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. 
  • Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative. 
  • Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. 
  • Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. 
  • Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. 
  • Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. 
  • Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. 
  • Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. 
  • Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction. 
  • Implementation of a Regional Network for ST-Segment-Elevation Myocardial Infarction (STEMI) Care and 30-Day Mortality in a Low- to Middle-Income City in Brazil: Findings From Salvador's STEMI Registry (RESISST). 
  • Implementation of a pharmacogenomics service in a community pharmacy. 
  • Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. 
  • Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction. 
  • Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction. 
  • Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account. 
  • Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. 
  • Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. 
  • Improving acute coronary syndrome care: the ACC/AHA guidelines and critical pathways. 
  • Improving documentation of anticoagulation and antiplatelet recommendations after outpatientendoscopy. 
  • In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events. 
  • In Reply: External Ventricular Drain and Hemorrhage in Aneurysmal Subarachnoid Hemorrhage Patients on Dual Antiplatelet Therapy: A Retrospective Cohort Study. 
  • In Reply: Safety and Efficacy Issues of Tirofiban Use in Endovascular Procedures: What Are the Actual Indications? 
  • In Reply: Tirofiban Protocol Protects Against Delayed Cerebral Ischemia: A Case-Series Study. 
  • In older patients with NSTE-ACS, clopidogrel safely reduced bleeding compared with ticagrelor at 1 year. 
  • In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel. 
  • In vitro effects of recombinant activated factor VIIa (NovoSeven) on clopidogrel-induced platelet inhibition. 
  • In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonists c7E3 Fab on the activated clotting time. 
  • In-Pipeline Stenosis: Incidence, Predictors, and Clinical Outcomes. 
  • In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin. 
  • In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. 
  • Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. 
  • Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. 
  • Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. 
  • Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb/IIIa platelet inhibitor era. 
  • Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. 
  • Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. 
  • Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. 
  • Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. 
  • Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. 
  • Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). 
  • Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. 
  • Incidence, outcomes, and management of bleeding in non-ST-elevation acute coronary syndromes. 
  • Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. 
  • Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches. 
  • Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. 
  • Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? 
  • Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. 
  • Independent predictors of stroke in patients with atrial fibrillation: a systematic review. 
  • Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review. 
  • Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? 
  • Infarct on Brain Imaging, Subsequent Ischemic Stroke, and Clopidogrel-Aspirin Efficacy: A Post Hoc Analysis of a Randomized Clinical Trial. 
  • Inflammation and circulating endothelial progenitor cells in patients with coronary artery disease and residual platelet reactivity. 
  • Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. 
  • Inflammation, platelets, and glycoprotein IIb/IIIa inhibitors. 
  • Influence of Amlodipine on Haemostatic Measurements during Clopidogrel Treatment in Patients with Coronary Artery Disease. 
  • Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. 
  • Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study. 
  • Influence of Sex on Platelet Reactivity in Response to Aspirin. 
  • Influence of clinical trial participation on subsequent antithrombin use. 
  • Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. 
  • Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment Evaluation. 
  • Influence of platelet reactivity on BARC classification in East Asian patients undergoing percutaneous coronary intervention. Results of the ACCEL-BLEED study. 
  • Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis. 
  • Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Inhibited and Uninhibited Platelet Deposition Within a Thrombus: Does It Depend on the Antiplatelet Drug? 
  • Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. 
  • Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction. 
  • Inhibitors of platelet adhesion. 
  • Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. 
  • Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. 
  • Initial platelet activity may predict efficacy after chronic oral glycoprotein IIb/IIIa blockade: should we still consider uniform treatment regimens? 
  • Integrating GP IIb/IIIa inhibition into treatment strategies for acute ST-elevation myocardial infarction. 
  • Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. 
  • Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. 
  • Interinstitutional variation in the use of abciximab for percutaneous coronary intervention. 
  • International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. 
  • Interpretation of platelet inhibition by clopidogrel and the effect of non-responders. 
  • Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. 
  • Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. 
  • Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. 
  • Investigating the mechanisms of hyporesponse to antiplatelet approaches. 
  • Investigator-Reported Versus Adjudicated Clinical Events: 2 Versions of the Truth? 
  • Is There a Role for Preoperative Platelet Function Testing in Patients Undergoing Cardiac Surgery During Antiplatelet Therapy? 
  • Is aspirin intake associated with early age-related macular degeneration? The Singapore Indian Eye Study. 
  • Is clopidogrel as the P2Y12 inhibitor a wise choice for long-term monotherapy in patients undergoing stenting? 
  • Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study. 
  • Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy? 
  • Is meta-analysis the optimal method to decide the duration of antiplatelet therapy in diabetic patients treated with drug‑eluting stenting? 
  • Is there a rationale for antiplatelet therapy in acute heart failure? 
  • Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. 
  • Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. 
  • Lack of association between serum paraoxonase-1 activity and residual platelet aggregation during dual anti-platelet therapy. 
  • Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy. 
  • Lessons learned from a clinical trial. 
  • Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease. 
  • Letter by Grbel et al regarding article, "administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome". 
  • Letter by Moris and Avgerinos Regarding Article, "Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone". 
  • Letter by Moris et al Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)". 
  • Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective. 
  • Limb ischemia: cardiovascular diagnosis and management from head to toe. 
  • Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis. 
  • Local administration of L-703,081 using a composite polymeric stent reduces platelet deposition in canine coronary arteries. 
  • Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. 
  • Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. 
  • Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. 
  • Long-term antithrombotic therapy after venous stent placement. 
  • Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions). 
  • Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. 
  • Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee. 
  • Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome. 
  • Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial. 
  • Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. 
  • Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study. 
  • Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. 
  • Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. 
  • Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. 
  • Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. 
  • Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. 
  • Low-dose versus high-dose aspirin after percutaneous coronary intervention: analysis from the guthrie health off-label StenT (GHOST) registry. 
  • Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. 
  • Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. 
  • Major bleeding: management and risk reduction in acute coronary syndromes. 
  • Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study. 
  • Management of Anticoagulant and Antiplatelet Medications in Adults Undergoing Percutaneous Interventions. 
  • Management of Anticoagulation/Antiplatelet Medication and Venous Thromboembolism Prophylaxis in Elective Spine Surgery: Concise Clinical Recommendations Based on a Modified Delphi Process. 
  • Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. 
  • Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR). 
  • Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR). 
  • Management of cardiogenic shock. 
  • Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. 
  • Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. 
  • Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. 
  • Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. 
  • Mechanical calf compression and aspirin prophylaxis for total knee arthroplasty. 
  • Medical economics and the assessment of value in cardiovascular medicine: Part II. 
  • Medical records and quality of care in acute coronary syndromes: results from CRUSADE. 
  • Medication performance measures and mortality following acute coronary syndromes. 
  • Medication, reperfusion therapy and survival in a community-based setting of hospitalised myocardial infarction. 
  • Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. 
  • Meta-Analysis Comparing the Safety and Efficacy of Dual Versus Single Antiplatelet Therapy After Transcatheter Aortic Valve Implantation. 
  • Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor. 
  • Minimizing the risks of anticoagulants and platelet inhibitors. 
  • Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? 
  • Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. 
  • Modern medical management of acute ischemic stroke. 
  • Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. 
  • Monitoring platelet inhibition during chronic oral platelet glycoprotein IIb/IIIa blockade: are we missing something? 
  • Morphine and Cardiovascular Outcomes Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Undergoing Coronary Angiography. 
  • Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trial. 
  • Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. 
  • Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. 
  • Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. 
  • Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling. 
  • Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. 
  • Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. 
  • Multifaceted Intervention to Improve P2Y12 Inhibitor Adherence After Percutaneous Coronary Intervention: A Stepped Wedge Trial. 
  • Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. 
  • Navigating the treacherous waters of antithrombotic therapies in patients with atrial fibrillation and coronary artery disease: Lessons from AUGUSTUS. 
  • New classes of anticoagulation and antiplatelet agents: preprocedure management and safety guidelines for imaging-guided intervention. 
  • New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. 
  • New transient ischemic attack and stroke: outpatient management by primary care physicians. 
  • New treatment approaches for osteonecrosis of the femoral head: an overview. 
  • Novel Antithrombotic Agents in Pregnancy Anticoagulants and Antiplatelet Agents. 
  • Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. 
  • Novel oral anticoagulants after acute coronary syndromes. 
  • Novel platelet antiaggregants and the changing landscape of stroke prevention. 
  • Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial. 
  • Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. 
  • Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. 
  • Odyssey of Patent Foramen Ovale: Closure in Cryptogenic Stroke: The Canary in the Coal Mine of Clinical Trials? 
  • Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel. 
  • Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. 
  • Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy). 
  • Optimal pediatric dosing of anti-platelet agents for pipeline stent embolization -a case report and review of the literature. 
  • Optimizing platelet P2Y12 inhibition for patients undergoing PCI. 
  • Oral anticoagulant therapy for the prevention of stroke. 
  • Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trial. 
  • Oral platelet IIb/IIIa inhibitors: from attractive theory to clinical failures. 
  • Oral platelet glycoprotein IIb/IIIa inhibition. 
  • Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. 
  • Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. 
  • Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization. 
  • Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. 
  • Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study. 
  • Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. 
  • Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. 
  • Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry. 
  • Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial). 
  • Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. 
  • Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study). 
  • Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC trial. 
  • Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). 
  • Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. 
  • Oxylipid Profile of Low-Dose Aspirin Exposure: A Pharmacometabolomics Study. 
  • P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. 
  • P2Y12 Receptor Blockade and Myocardial Perfusion. 
  • P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. 
  • P2Y12 receptor inhibitors for secondary prevention of ischemic stroke. 
  • PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. 
  • PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies. 
  • PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis. 
  • PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. 
  • Patient-reported frequency of taking aspirin in a population with coronary artery disease. 
  • Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation. 
  • Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. 
  • Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative. 
  • Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. 
  • Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative). 
  • Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. 
  • Percutaneous coronary intervention in a patient with immune thrombocytopenia purpura. 
  • Peri-operative platelet function testing: the potential for reducing ischaemic and bleeding risks. 
  • Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention. 
  • Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH. 
  • Perioperative Considerations in Management of the Severely Bleeding Coagulopathic Patient. 
  • Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. 
  • Perioperative Management of the Gynecologic Patient on Long-term Anticoagulation. 
  • Perioperative anticoagulation and antiplatelet therapy in renal transplant: is there an increase in bleeding complication? 
  • Perioperative management of a neurosurgical patient requiring antiplatelet therapy. 
  • Perioperative management of patients on chronic antithrombotic therapy. 
  • Perioperative management of patients on clopidogrel (Plavix) undergoing major lung resection. 
  • Peripartum management of dual antiplatelet therapy and neuraxial labor analgesia after bare metal stent insertion for acute myocardial infarction. 
  • Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy: communication from the SSC of the ISTH. 
  • Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. 
  • Persistent thrombocytopaenia in a young man with splenomegaly, rebound thrombocytosis after splenectomy and subsequent pulmonary embolism: splenic littoral cell angioma and associated events. 
  • Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials. 
  • Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy. 
  • Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction. 
  • Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial. 
  • Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention. 
  • Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. 
  • Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study. 
  • Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response. 
  • Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading: the results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study. 
  • Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) study. 
  • Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. 
  • Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. 
  • Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. 
  • Pharmacogenetic guidance for antiplatelet treatment. 
  • Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists. 
  • Pharmacogenetics of Clopidogrel: An Unresolved Issue. 
  • Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. 
  • Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. 
  • Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction. 
  • Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation. 
  • Pharmacology of antiplatelet agents. 
  • Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens. 
  • Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. 
  • Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients. 
  • Pipeline-assisted coiling versus pipeline in flow diversion treatment of intracranial aneurysms. 
  • Platelet Function Testing in Patients on Antiplatelet Therapy before Cardiac Surgery. 
  • Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies. 
  • Platelet RNA as a novel biomarker for the response to antiplatelet therapy. 
  • Platelet Reactivity and Coagulation Markers in Patients with COVID-19. 
  • Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study. 
  • Platelet activation and its patient-specific consequences. 
  • Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? 
  • Platelet activity associated with concomitant use of clopidogrel and proton pump inhibitors in children with cardiovascular disease. 
  • Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. 
  • Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. 
  • Platelet function and pharmacologic inhibition. 
  • Platelet function measurement in elective percutaneous coronary intervention patients: exploring the concept of a P2Y₁₂ inhibitor therapeutic window. 
  • Platelet function monitoring in patients with coronary artery disease. 
  • Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. 
  • Platelet glycoprotein IIb/IIIa integrin blockade: recent clinical trials in interventional cardiology. 
  • Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection. 
  • Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. 
  • Platelet inhibition by low-dose aspirin is not influenced by body mass or weight. 
  • Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. 
  • Platelet inhibition strategies in percutaneous coronary intervention: competition or coopetition? 
  • Platelet inhibition to target reperfusion injury trial: Rationale and study design. 
  • Platelet inhibition with cangrelor in patients undergoing PCI. 
  • Platelet inhibitors and bleeding in cardiac surgical patients. 
  • Platelet inhibitors and cardiac surgery. 
  • Platelet inhibitors: what are the data in women? 
  • Platelet monitoring for PCI: is it really necessary? 
  • Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. 
  • Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans. 
  • Platelet response in practice: Applying new insights and tools for testing and treatment. 
  • Platelet-Mediated Thrombosis: From Bench to Bedside. 
  • Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. 
  • Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. 
  • Platelets in atherothrombosis. 
  • Pneumatic compression or aspirin prophylaxis against thromboembolism in total hip arthroplasty. 
  • Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. 
  • Point-of-care platelet function analysis ready for prime time? 
  • Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study. 
  • Polymorphisms associated with in vitro aspirin resistance are not associated with clinical outcomes in patients with coronary artery disease who report regular aspirin use. 
  • Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. 
  • Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy. 
  • Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. 
  • Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. 
  • Post-coronary intervention recurrent ischemia in the presence of adequate platelet inhibition by dual antiplatelet therapy: what are we overlooking? 
  • Postmenopausal hormone use in women with acute coronary syndromes. 
  • Postprocedural Antithrombotic Therapy Following Left Atrial Appendage Occlusion: No Longer Adrift in Uncertainty? 
  • Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial. 
  • Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran. 
  • Power calculations for large multi-arm placebo-controlled studies of dichotomous outcomes. 
  • Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial. 
  • Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. 
  • Prasugrel Use Following PCI and Associated Patient Outcomes: Insights From the National VA CART Program. 
  • Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients. 
  • Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. 
  • Prasugrel versus clopidogrel for acute coronary syndromes. 
  • Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. 
  • Prasugrel vs. Ticagrelor for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. 
  • Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel. 
  • Prasugrel, a third generation thienopyridine and potent platelet inhibitor. 
  • Prasugrel. 
  • Prasugrel: Clinical development and therapeutic application. 
  • Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. 
  • Pre-hospital treatment with crushed versus integral tablets of prasugrel in patients presenting with ST-Segment Elevation Myocardial Infarction-1-year follow-up results of the COMPARE CRUSH trial. 
  • Precatheterization Use of P2Y12 Inhibitors in Non-ST-Elevation Myocardial Infarction Patients Undergoing Early Cardiac Catheterization and In-Hospital Coronary Artery Bypass Grafting: Insights From the National Cardiovascular Data Registry®. 
  • Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. 
  • Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population. 
  • Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. 
  • Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. 
  • Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. 
  • Predictors of stroke in patients paced for sick sinus syndrome. 
  • Prehospital electrocardiograms (ECGs) do not improve the process of emergency department care in hospitals with higher usage of ECGs in non-ST-segment elevation myocardial infarction patients. 
  • Prehospital treatment with zalunfiban (RUC-4) in patients with ST- elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial. 
  • Prehospitalization antiplatelet therapy and outcomes after saphenous vein graft intervention. 
  • Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. 
  • Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. 
  • Prestroke and Poststroke Antithrombotic Therapy in Patients With Atrial Fibrillation: Results From a Nationwide Cohort. 
  • Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. 
  • Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials. 
  • Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. 
  • Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. 
  • Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. 
  • Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. 
  • Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent. 
  • Primary prevention of stroke. 
  • Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. 
  • Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Procedural and clinical outcomes after use of the glycoprotein IIb/IIIa inhibitor abciximab for saphenous vein graft interventions. 
  • Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. 
  • Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. 
  • Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. 
  • Prognostic significance of bleeding location and severity among patients with acute coronary syndromes. 
  • Prognostic significance of elevated troponin I after percutaneous coronary intervention. 
  • Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial). 
  • Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. 
  • Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). 
  • Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. 
  • Protection of Distal Embolization in High-Risk Patients with Acute ST-Segment Elevation Myocardial Infarction (PREMIAR). 
  • Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). 
  • Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics. 
  • Quality of care for atrial fibrillation among patients hospitalized for heart failure. 
  • Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial. 
  • Racial differences in long-term outcomes among black and white patients with drug-eluting stents. 
  • Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. 
  • Randomisation in the SYMPHONY trial. 
  • Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. 
  • Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. 
  • Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. 
  • Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. 
  • Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. 
  • Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. 
  • Randomized comparison of primary percutaneous coronary intervention with combined proximal embolic protection and thrombus aspiration versus primary percutaneous coronary intervention alone in ST-segment elevation myocardial infarction: the PREPARE (PRoximal Embolic Protection in Acute myocardial infarction and Resolution of ST-Elevation) study. 
  • Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. 
  • Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. 
  • Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. 
  • Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. 
  • Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. 
  • Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor. 
  • Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. 
  • Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. 
  • Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. 
  • Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial. 
  • Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). 
  • Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial. 
  • Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. 
  • Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). 
  • Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. 
  • Readministration of abciximab: interim report of the ReoPro readministration registry. 
  • Rear-view mirror observations on bleeding in acute coronary syndromes. 
  • Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. 
  • Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. 
  • Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. 
  • Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. 
  • Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts. 
  • Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid. 
  • Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. 
  • Reducing cardiac events after acute coronary syndromes. 
  • Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade. 
  • Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. 
  • Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. 
  • Relation between inhibition of platelet aggregation and clinical outcomes. 
  • Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading. 
  • Relation of Activated Clotting Times During Percutaneous Coronary Intervention to Outcomes. 
  • Relation of High Lipoprotein (a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease. 
  • Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study. 
  • Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. 
  • Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. 
  • Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. 
  • Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. 
  • Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy. 
  • Reoperation for bleeding in patients undergoing coronary artery bypass surgery: incidence, risk factors, time trends, and outcomes. 
  • Reperfusion for acute myocardial infarction: is the future in plastics? 
  • Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease. 
  • Reperfusion synergism: will it be both sustained and safe? 
  • Reply to effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with Clopidogrel. 
  • Resistance to antiplatelet drugs: current status and future research. 
  • Resistance to antiplatelet drugs: what progress has been made? 
  • Resource use and costs of treatment with anticoagulation and antiplatelet agents: results of the WATCH trial economic evaluation. 
  • Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". 
  • Response to letters regarding article, “Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy”. 
  • Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. 
  • Response variability and the role of platelet function testing. 
  • Results of recent large myocardial infarction trials, adjunctive therapies, and acute myocardial infarction: improving outcomes. 
  • Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin. 
  • Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions. 
  • Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. 
  • Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital. 
  • Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan　- Insights From GARFIELD-AF. 
  • Risk factor profile and management of cerebrovascular patients in the REACH Registry. 
  • Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial. 
  • Risk factors for cerebrovascular events following fontan palliation in patients with a functional single ventricle. 
  • Risk of hemorrhagic complication associated with ventriculoperitoneal shunt placement in aneurysmal subarachnoid hemorrhage patients on dual antiplatelet therapy. 
  • Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. 
  • Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. 
  • Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. 
  • Risk of ventriculostomy-related hemorrhage in patients with acutely ruptured aneurysms treated using stent-assisted coiling. 
  • Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. 
  • Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator. 
  • Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention. 
  • Rivaroxaban Plus Aspirin After CABG: More Evidence Is Needed. 
  • Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. 
  • Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. 
  • Rivaroxaban in Peripheral Artery Disease after Revascularization. 
  • Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. 
  • Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial. 
  • Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. 
  • Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. 
  • Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. 
  • Road mapping ATLAS ACS 2: are we there yet? 
  • Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors. 
  • Roundtable panel discussion: the role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes. 
  • Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. 
  • Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. 
  • S-nitrosoglutathione/glutathione disulphide/Cu2+-dependent stimulation of L-arginine transport in human platelets. 
  • SK&F 96365, a novel inhibitor of receptor-mediated calcium entry. 
  • ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. 
  • ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. 
  • Safety and Efficacy of a 600-mg Loading Dose of Clopidogrel 24 Hours Before Pipeline Embolization Device Treatment. 
  • Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses: A Meta-Analysis. 
  • Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. 
  • Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. 
  • Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials. 
  • Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery. 
  • Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. 
  • Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. 
  • Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. 
  • Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. 
  • Safety and efficacy of tirofiban in stent-assisted coil embolization of intracranial aneurysms. 
  • Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. 
  • Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. 
  • Safety of Dual-Antiplatelet Therapy After Myocardial Infarction Among Patients With Chronic Kidney Disease. 
  • Safety of abciximab administration during PCI of patients with previous stroke. 
  • Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. 
  • Safety of tirofiban and dual antiplatelet therapy in treating intracranial aneurysms. 
  • Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV. 
  • Secondary prevention of ischaemic stroke: more evidence to block two pathways affecting platelet activation. 
  • Seeking the optimal aspirin dose in acute coronary syndromes. 
  • Selection of Stent Type in Patients With Atrial Fibrillation Presenting With Acute Myocardial Infarction: An Analysis From the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry-Get With the Guidelines. 
  • Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. 
  • Sensitive troponin I assay in patients with suspected acute coronary syndrome. 
  • Sex And Prognostic Significance of Self-Reported Frailty in Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial. 
  • Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. 
  • Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. 
  • Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. 
  • Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. 
  • Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. 
  • Sex-based differences in outcomes after percutaneous coronary intervention for acute myocardial infarction: a report from TRANSLATE-ACS. 
  • Sex-stratified differences in early antithrombotic treatment response in patients presenting with ST-segment elevation myocardial infarction. 
  • Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. 
  • Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis. 
  • Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians? 
  • Sinusitis: allergies, antibiotics, aspirin, asthma. 
  • Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. 
  • Small-molecule glycoprotein IIb/IIIa inhibitors as adjunctive therapy in percutaneous coronary interventions. 
  • Smoking and cardiovascular diseases: paradox greater than expected? 
  • Sonorheometry assessment of platelet function in cardiopulmonary bypass patients: Correlation of blood clot stiffness with platelet integrin αIIbβ3 activity, aspirin usage, and transfusion risk. 
  • Sources of hospital-level variation in major bleeding among patients with non-st-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry (NCDR). 
  • Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. 
  • Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. 
  • Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. 
  • Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. 
  • Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. 
  • Statins do not affect platelet inhibition with clopidogrel during coronary stenting. 
  • Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials. 
  • Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial. 
  • Stent thrombosis: role of compliance and nonresponsiveness to antiplatelet therapy. 
  • Stent-assisted coiling of wide-necked aneurysms in the setting of acute subarachnoid hemorrhage: experience in 65 patients. 
  • Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. 
  • Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2-VASc Scores: Findings From the ORBIT-AF I and II Registries. 
  • Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. 
  • Strokelore: Antithrombotic therapy and hemorrhagic infarction. 
  • Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. 
  • Sustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry. 
  • Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. 
  • Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. 
  • Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. 
  • Synthesis and biological characterization of sqbazide, a novel biotinylated photoaffinity probe for the study of the human platelet thromboxane A2 receptor. 
  • Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. 
  • Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction. 
  • Targeting patients undergoing angioplasty for thrombus inhibition: a cost-effectiveness and decision support model. 
  • Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience. 
  • Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry. 
  • Temporal trends in medical therapies for ST- and non-ST elevation myocardial infarction: (from the Atherosclerosis Risk in Communities [ARIC] Surveillance Study). 
  • The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. 
  • The CHD challenge: comparing four cost-effectiveness models. 
  • The Dogged Search for Cryptic Effects of Ticagrelor: Wishful Thinking or Real Benefits Beyond P2Y12 Inhibition? 
  • The EPILOG trial. Abciximab prevents ischemic complications during angioplasty. Evaluation in PTCA to improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade. 
  • The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. 
  • The Editor's Roundtable: arterial thrombosis and acute coronary syndromes. 
  • The Evolving Post-PCI Antithrombotic Therapies. 
  • The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease. 
  • The Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study: Variation in Platelet Response to Clopidogrel and Aspirin. 
  • The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial. 
  • The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. 
  • The Role of Antiplatelet Therapy in Primary Prevention. A Review. 
  • The Safety and Efficacy of Continuous Tirofiban as a Monoantiplatelet Therapy in the Management of Ruptured Aneurysms Treated Using Stent-Assisted Coiling or Flow Diversion and Requiring Ventricular Drainage. 
  • The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. 
  • The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. 
  • The anticoagulated patient: strategies for effective blood loss management. 
  • The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. 
  • The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction. 
  • The benefit of abciximab in percutaneous coronary revascularization is not device-specific. 
  • The clopidogrel-statin interaction. 
  • The complementary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention. 
  • The current state of antiplatelet therapy in acute coronary syndromes: the data and the real world. 
  • The early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition. 
  • The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. 
  • The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. 
  • The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. 
  • The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. 
  • The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. 
  • The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. 
  • The effects of milrinone on platelets in patients undergoing cardiac surgery. 
  • The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. 
  • The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis. 
  • The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • The enigmatic search for optimal DAPT duration. 
  • The evolution of platelet-directed pharmacotherapy. 
  • The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. 
  • The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. 
  • The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention. 
  • The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. 
  • The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. 
  • The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial. 
  • The management of acute coronary syndromes in patients with chronic kidney disease. 
  • The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative. 
  • The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 
  • The pharmacogenetics of antiplatelet agents: towards personalized therapy? 
  • The power of more than one. 
  • The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. 
  • The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. 
  • The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome. 
  • The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. 
  • The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. 
  • The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. 
  • The relationship between meteorological conditions and index acute coronary events in a global clinical trial. 
  • The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. 
  • The reply. 
  • The role of glycoprotein IIb/IIIa platelet inhibition in percutaneous coronary intervention in the stent era. 
  • The role of platelet function testing and genotyping in the stented patient treated with clopidogrel. 
  • The role of prasugrel in the management of acute coronary syndromes: a systematic review. 
  • The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. 
  • The truth and consequences of the COURAGE trial. 
  • The use of alternatives to clopidogrel in flow-diversion treatment with the Pipeline embolization device. 
  • The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends. 
  • The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient. 
  • Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. 
  • Therapies to prevent heart failure post-myocardial infarction. 
  • Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. 
  • Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. 
  • Thrombocyte Inhibition Restores Protective Immunity to Mycobacterial Infection in Zebrafish. 
  • Thromboelastography detects inadequate response to abciximab therapy during stent-assisted cerebral aneurysm coil embolization complicated by stroke. 
  • Thromboembolic Events with Enterprise Versus Pipeline: Porcine In Vivo Experiment. 
  • Thromboembolism after WATCHMANTM in a clopidogrel non-responder: A case for concern? 
  • Thrombolytic, antithrombin, and antiplatelet treatment of acute coronary syndromes. 
  • Thrombophilia and thrombosis in thrombotic thrombocytopenic purpura. 
  • Thrombosis and drug-eluting stents: an objective appraisal. 
  • Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy. 
  • Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. 
  • Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. 
  • Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. 
  • Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. 
  • Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. 
  • Ticagrelor for the treatment of arterial thrombosis. 
  • Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution. 
  • Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. 
  • Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. 
  • Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. 
  • Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. 
  • Ticagrelor versus Clopidogrel in Peripheral Artery Disease. 
  • Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. 
  • Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. 
  • Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. 
  • Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Ticagrelor versus clopidogrel in patients with acute coronary syndromes. 
  • Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. 
  • Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis. 
  • Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. 
  • Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. 
  • Ticagrelor with or without Aspirin in High-Risk Patients after PCI. 
  • Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). 
  • Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). 
  • Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. 
  • Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation. 
  • Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. 
  • Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial. 
  • Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel: The Role of VerifyNow. 
  • Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. 
  • Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials. 
  • Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). 
  • Tirofiban Protocol Protects Against Delayed Cerebral Ischemia: A Case-Series Study. 
  • Tissue plasminogen activator for acute ischemic stroke. 
  • Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. 
  • Toward a therapeutic window for antiplatelet therapy in the elderly. 
  • Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. 
  • Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. 
  • Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. 
  • Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps? 
  • Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events). 
  • Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. 
  • Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. 
  • Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). 
  • Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. 
  • Treatment of blister-like aneurysms with the pipeline embolization device. 
  • Treatment of mechanical aortic valve thrombosis with heparin and eptifibatide. 
  • Treatment of non-ST-segment-elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors: an emergency department perspective. 
  • Treatment strategies for microvascular dysfunction following acute myocardial infarction. 
  • Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. 
  • Treatment with adenosine diphosphate receptor inhibitors-longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study design: expanding the paradigm of longitudinal observational research. 
  • Treatments-Preventive. 
  • Trends in the use of evidence-based treatments for coronary artery disease among women and the elderly: findings from the get with the guidelines quality-improvement program. 
  • Triple Therapy for Atrial Fibrillation after PCI. 
  • Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. 
  • Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. 
  • Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. 
  • Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry. 
  • Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. 
  • Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. 
  • Two-year outcomes after transcatheter or surgical aortic-valve replacement. 
  • US National Survey of Physician Practices for the Secondary and Tertiary Prevention of Ischemic Stroke. Medical therapy in patients with carotid artery stenosis. 
  • US Surveillance of Acute Ischemic Stroke Patient Characteristics, Care Quality, and Outcomes for 2019. 
  • Understanding operator stent choice in the catheterization laboratory using a pre-procedure survey: Opportunities for quality improvement. 
  • Understanding the Adverse Effects of Ticagrelor in Practice. 
  • Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. 
  • Underuse of aspirin in a referral population with documented coronary artery disease. 
  • Uniform platelet activation exists before coronary stent implantation despite aspirin therapy. 
  • Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y₁₂ inhibitors. 
  • Unsticking platelets: the role of glycoprotein IIb/IIIa receptor blockade. 
  • Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. 
  • Update: Acute coronary syndromes (V). Personalized antiplatelet therapy. 
  • Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. 
  • Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. 
  • Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. 
  • Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States. 
  • Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation. 
  • Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. 
  • Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. 
  • Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. 
  • Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). 
  • Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). 
  • Use of aspirin associates with longer primary patency of hemodialysis grafts. 
  • Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. 
  • Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. 
  • Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. 
  • Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction. 
  • Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. 
  • Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. 
  • Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. 
  • Vale, warfarin: a stentorian farewell. 
  • Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. 
  • Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial. 
  • Variability of antiplatelet response in patients with peripheral artery disease. 
  • Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry. 
  • Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. 
  • Vorapaxar in the secondary prevention of atherothrombosis. 
  • Vorapaxar in the secondary prevention of atherothrombotic events. 
  • Vorapaxar in the treatment of cardiovascular diseases. 
  • Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. 
  • Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. 
  • Vorapaxar: a novel protease-activated receptor-1 inhibitor. 
  • Warfarin or aspirin for recurrent ischemic stroke. 
  • Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. 
  • We need further studies for the development of "optimized antiplatelet therapy" based on ethnicity. 
  • We need to do better for patients with non-ST-segment elevation acute coronary syndrome who are managed without revascularization. 
  • What is the best measure of thrombotic risks--pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation? 
  • What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention? 
  • White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). 
  • Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons? 
  • YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. 
  • [Antiplatelet and anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation: evidence based strategies and new developments]. 
  • [Brazilian guidelines on platelet antiaggregants and anticoagulants in cardiology]. 
  • [ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)]. 
  • [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. 
  • [Livedoid vasculopathy with heterozygous factor V Leiden mutation and sticky platelet syndrome]. 
  • [Predictive value of the GRACE discharge score on the long-term out-of-hospital coronary thrombotic events after implantation of drug-eluting stents]. 
  • [The role of clopidogrel in cardiovascular diseases]. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Science & Society
  • Middleton, John Paul, Professor of Medicine, Medicine, Nephrology
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Voora, Deepak, Associate Professor of Medicine, Medicine, Cardiology